Examples of using Bone resorption in English and their translations into Polish
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Financial
-
Official/political
-
Programming
-
Computer
Urinary concentrations of the bone resorption marker CTx(C-terminal telopeptide released from Type I collagen) were significantly reduced in the Bondronat group compared to placebo.
levels after menopause or oophorectomy lead to accelerated bone loss due to increased bone turnover, where bone resorption exceeds bone formation.
which means that bone resorption is most pronounced in areas where myeloma cells are found.
Potency of the medicinal product that inhibits bone resorption(higher risk for highly potent compounds),
reduces bone resorption by decreasing osteoclast differentiation
route of administration(higher risk for parenteral administration) and cumulative dose of bone resorption therapy.
Potency of the medicinal product that inhibit bone resorption(higher risk for highly potent compounds), route of administration(higher risk for parenteral administration) and cumulative dose of bone resorption therapy.
reaching a nadir for the bone resorption marker serum type 1 C-telopeptides(CTX)(85% reduction)
In some patients with chronic kidney disease, bone resorption starts around the teeth
the product should not be used for direct applications to trabecular bone where transient bone resorption may create a risk of bone fragility see section 4.8.
Therefore, in the absence of clinical data, the veterinary medicinal product should not be used for direct applications to trabecular bone when transient bone resorption may create a risk of bone fragility
total ALP and procollagen I N propeptide[PINP], bone resorption markers: C-terminal crosslinking telopeptide of type I collagen[S-CTX-I]
It is an inhibitor of osteoclastic bone resorption.
Inhibition of osteoclastic bone resorption, which alters the bone marrow.
With no further dosing, there is a loss of suppression of biochemical markers of bone resorption.
Following treatment discontinuation, there is a reversion to the pathological pre-treatment rates of elevated bone resorption associated with postmenopausal osteoporosis.
thereby decreasing bone resorption in cortical and trabecular bone. .
The decrease in oestrogen availability which occurs at menopause, leads to marked increases in bone resorption, bone loss
In young(fast growing) rats, the endogenous bone resorption is also inhibited, leading to increased normal
The inhibition of endogenous bone resorption has also been documented by 45Ca kinetic studies